This segment focuses on developing and commercializing theranostic solutions for sepsis and septic shock. Key activities include the ongoing Tigris trial, which evaluates the efficacy of Polymyxin B Hemoperfusion (PMX) in conjunction with the Endotoxin Activity Assay (EAA) to guide treatment decisions. The EAA is a rapid diagnostic test that detects endotoxins, enabling personalized treatment strategies. Research efforts are directed towards identifying biomarkers and refining patient selection criteria to improve outcomes. The goal is to reduce mortality and morbidity associated with sepsis by providing targeted therapies based on individual patient profiles. Collaborations with commercialization partners are crucial for expanding market reach and ensuring widespread adoption of these innovative solutions.

This segment is dedicated to the development, manufacturing, and marketing of products for detecting and managing endotoxins in the bloodstream. The primary product is the Endotoxin Activity Assay (EAA), an in vitro diagnostic test used to detect gram-negative bacterial cell wall components. Research and development efforts focus on improving the sensitivity and specificity of the EAA, as well as exploring new applications for endotoxin detection in various clinical settings. The segment also includes the Polymyxin B Hemoperfusion (PMX) device, a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream. The goal is to provide clinicians with tools to rapidly identify and manage endotoxemia, a critical factor in the pathogenesis of septic shock. Future opportunities include expanding the use of EAA and PMX in other inflammatory conditions and developing new endotoxin-targeting therapies.